Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Acetates
/ pharmacology
Animals
Arthritis, Rheumatoid
/ drug therapy
Biomarkers
/ metabolism
Cyclopropanes
Cytokines
/ metabolism
Leukotriene Antagonists
/ pharmacology
Leukotrienes
/ metabolism
Oxidative Stress
/ drug effects
Quinolines
/ pharmacology
Rats
Rats, Wistar
Receptors, Leukotriene
/ metabolism
Sulfides
Cytokines
Eicosanoids
Inflammation
Montelukast
Rheumatoid arthritis
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
24
05
2019
accepted:
24
06
2019
pubmed:
17
7
2019
medline:
28
11
2019
entrez:
17
7
2019
Statut:
ppublish
Résumé
Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis. Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route. Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were significantly (p < 0.05) reduced in montelukast administered rats. Paw inflammation, RA markers (RF and CRP), eicosanoids (PGE
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis.
METHODS
METHODS
Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route.
RESULTS AND DISCUSSION
CONCLUSIONS
Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were significantly (p < 0.05) reduced in montelukast administered rats. Paw inflammation, RA markers (RF and CRP), eicosanoids (PGE
Identifiants
pubmed: 31309487
doi: 10.1007/s10787-019-00618-0
pii: 10.1007/s10787-019-00618-0
doi:
Substances chimiques
Acetates
0
Biomarkers
0
Cyclopropanes
0
Cytokines
0
Leukotriene Antagonists
0
Leukotrienes
0
Quinolines
0
Receptors, Leukotriene
0
Sulfides
0
leukotriene D4 receptor
LRF7RW46ID
montelukast
MHM278SD3E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
923-931Subventions
Organisme : Department of Biotechnology, New Delhi, India
ID : GAP-472
Références
Abramson SB, Amin A (2002) Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 41(9):972–980
doi: 10.1093/rheumatology/41.9.972
Bieth J, Spiess B, Wermuth CG (1974) The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. Biochem Med 11(4):350–357
doi: 10.1016/0006-2944(74)90134-3
Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM (2011) Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 12(1):114
doi: 10.1186/1465-9921-12-114
Bousquet J, Demoly P, Humbert M (2009) Montelukast in guidelines and beyond. Adv Ther 26(6):575–587
doi: 10.1007/s12325-009-0038-1
Brand D, Latham KA, Rosloniec EF (2007) Collagen-induced arthritis. Nat Protoc 2(5):1269–1275
doi: 10.1038/nprot.2007.173
Bray MA, Cunningham FM, Ford-Hutchinson AW, Smith MJ (1981) Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol 72(3):483–486
doi: 10.1111/j.1476-5381.1981.tb11000.x
Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 32(1–2):23–38
doi: 10.1016/S0009-8981(03)00003-2
Goronzy JJ, Weyand CM (2009) Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 11(5):249
doi: 10.1186/ar2758
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite and [
doi: 10.1016/0003-2697(82)90118-X
Gruenwald J, Graubaum HJ, Hansen K, Grube B (2004) Efficacy and tolerability of a combination of lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Adv Ther 21(3):197–201
doi: 10.1007/BF02850125
Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS (2008) 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes 57(5):1387–1393
doi: 10.2337/db07-1217
Hamid Q, Tulic MK, Liu MC, Moqbel R (2003) Inflammatory cells in asthma: mechanisms and implications for therapy. J Aller Clin Immunol 111(1):S5–S17
doi: 10.1067/mai.2003.22
Honda T, Segi-Nishida E, Miyachi Y, Narumiya S (2006) Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203(2):325–335
doi: 10.1084/jem.20051310
Kahlenberg JM, Fox DA (2011) Advances in the medical treatment of rheumatoid arthritis. Hand Clin 27(1):11–20
doi: 10.1016/j.hcl.2010.09.002
Kang JH, Lim H, Yim DSM (2018) Montelukast inhibits RANKL-induced osteoclast formation and bone loss via CysLTR1 and P2Y12. Mol Med Rep 18(2):2387–2398
pubmed: 29916540
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW (2003) Treatment of rheumatoid arthritis by selective inhibition of T cell activation with fusion protein CTLA4Ig. N Engl J Med 349(20):1907–1915
doi: 10.1056/NEJMoa035075
Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA, Woolf CJ (2006) Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319(3):1096–1103
doi: 10.1124/jpet.106.105569
Lokesh BR, Hsieh HL, Kinsella JE (1986) Alterations in the lipids and prostaglandins in mouse spleen following the ingestion of menhaden oil. Ann Nutr Metab 30(6):357–364
doi: 10.1159/000177215
Martel-Pelletier J, Pelletier JP, Fahmi H (2003) Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 33(3):155–167
doi: 10.1016/S0049-0172(03)00134-3
Mathews MB, Dorfman A (1955) Inhibition of hyaluronidase. Physiol Rev 35(2):381–402
doi: 10.1152/physrev.1955.35.2.381
McInnes IB, Schet G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219
doi: 10.1056/NEJMra1004965
Mesquita CS, Oliveira R, Bento F, Geraldo D, Rodrigues JV, Marcos JC (2014) Simplified 2, 4-dinitrophenylhydrazine spectrophotometric assay for quantification of carbonyls in oxidized proteins. Anal Biochem 458:69–71
doi: 10.1016/j.ab.2014.04.034
Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351–358
doi: 10.1016/0003-2697(79)90738-3
Ong CK, Lirk P, Tan CH, Seymour RA (2007) An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 5(1):19–34
doi: 10.3121/cmr.2007.698
Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N (1995) Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 96(5):2357–2363
doi: 10.1172/JCI118292
Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8(11):656–664
doi: 10.1038/nrrheum.2012.153
Shah R, Raska KJr, Tiku ML (2005) The presence of molecular markers of in vivo lipid peroxidation in osteoarthritic cartilage: a pathogenic role in osteoarthritis. Arthritis Rheum 52(9):2799–2807
doi: 10.1002/art.21239
Shaw T, Quan J, Totoritis M (2003) B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62(2):55–59
Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007) Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56(8):2608–2619
doi: 10.1002/art.22794
Sprague AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78(6):539–552
doi: 10.1016/j.bcp.2009.04.029
Van Wart HE, Steinbrink DR (1981) A continuous spectrophotometric assay for clostridium histolyticum collagenase. Anal Biochem 113(2):356–365
doi: 10.1016/0003-2697(81)90089-0
Vijaykumar M, Sambaiah K, Lokesh BR (1999) The anhydrous milk fat lowers serum prostaglandins and secretion of leukotrienes by rat peritoneal macrophages. Prostaglandins Leukot Essent Fatty Acids 61(4):249–254
doi: 10.1054/plef.1999.0097